Companies: 10,795·Total market cap: $144.5T
Evogene Ltd.

Evogene Ltd.

EVGNNASDAQHealthcare● Active
$0.58
$-0.04(-5.82%)
Market Cap$5023607
P/E Ratio—
52W High$2.42
52W Low$0.52
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Evogene Ltd. (EVGN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001574565 · EVGN · NASDAQ · as of Jun 9, 2026

Filing snapshot

426
Total Filings
424B3
Latest Form
2026-05-20
Most Recent
2010
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001574565 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-26
Fiscal Year End
Mar 26, 2026
Accession No.
0001178913-26-001767
Primary Document
zk2634882.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001574565 · Accession 0001178913-26-001767

Latest Key Filings

6-KQuarterly Report
6-K
2026-05-20
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
424B3424B3
424B3
2026-05-20
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-20
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-18
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
EFFECTEFFECT
EFFECT
2026-04-15
View
CORRESPCORRESP
CORRESP
2026-04-13
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-04-09
View
EFFECTEFFECT
EFFECT
2026-04-03
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-02
View
UPLOADUPLOAD
UPLOAD
2026-04-01
View
F-3F-3
F-3
2026-03-26
View
S-8Employee Stock Plan Registration
S-8
2026-03-26
View
POS AMPOS AM
POS AM
2026-03-26
View
20-FAnnual Report (Foreign Issuer)
20-F
2026-03-26
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-18
View
Showing 1–15 of 426 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001574565  |  Exchange: NASDAQ · Healthcare

Evogene Ltd. (NASDAQ: EVGN) has submitted 426 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2010. As a Healthcare sector company with CIK 0001574565, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Evogene Ltd.'s most comprehensive regulatory disclosure. The most recent Evogene Ltd. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical EVGN 10-K annual reports are available from 2013 through 2026.

Investors researching Evogene Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
GLTO SEC Filings →CING SEC Filings →SNSE SEC Filings →MRKR SEC Filings →COCP SEC Filings →BOLT SEC Filings →AEON SEC Filings →CLRB SEC Filings →
→ EVGN Financials→ EVGN Earnings→ EVGN Insider Trades

Frequently Asked Questions

EVGN SEC Filings · 8 questions

Evogene Ltd. (EVGN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 426 filings and access original documents at no cost. Evogene Ltd.'s CIK is 0001574565.

EVGN SEC filingsEvogene Ltd. SEC documentsfind EVGN 10-K